<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01627171</url>
  </required_header>
  <id_info>
    <org_study_id>RP 12-3657</org_study_id>
    <nct_id>NCT01627171</nct_id>
  </id_info>
  <brief_title>Colonoscopy Preparation Optimization for INpatients- COIN Study</brief_title>
  <acronym>COIN</acronym>
  <official_title>A Randomized Control Trial Comparing 4L PEGlyte to Regular Dose Pico-Salax and Split Dose Pico-Salax for Colonoscopy Bowel Preparation in Hospitalized Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Joseph's Healthcare Hamilton</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>McMaster University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>St. Joseph's Healthcare Hamilton</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Colonoscopic examinations are performed routinely in hospitalized patients for a variety of
      indications. However, numerous limitations exist in hospitalized patients preventing an
      endoscopist from performing high quality examinations; possibly necessitating repeated
      procedures leading to increased cost and re-exposure to their inherent risks. One such
      prominent challenge lays in the adequacy of bowel cleansing. Inpatient status has been shown
      to be a predictor of poor bowel preparation as these patients are older, less mobile and have
      more co morbidities than the outpatient population. Currently, no standardized (or optimized)
      bowel preparation type or regimen for administration exists for the hospital inpatient
      population undergoing colonoscopy. Studies in the outpatient population have demonstrated
      that timing and choice of cathartic medication effects the cleanliness of the bowel
      preparation but there is no such clinical evidence for in-patients who receive whatever
      cathartic agent is on hospital formulary. The purpose of the study is compare efficacy,
      patient satisfaction, and adverse effects associated with low volume cathartic (Pico-Salax)
      to the current standard volume 4 liter (PEG-Lyte) and the effect of alternate timing of
      dosages.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2012</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ottawa Bowel Prep Score</measure>
    <time_frame>30 minutes after procedure</time_frame>
    <description>Using a standardized, validated score for measuring quality of bowel preparation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Procedures Cancelled or repeated due to inadequate bowel preparation</measure>
    <time_frame>During admission (average of 2 weeks)</time_frame>
    <description>If bowel preparation is deemed inadequate to the point the procedure must be cancelled or rescheduled</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Individual Components of Ottawa Bowel Prep Score</measure>
    <time_frame>30 minutes after procedure</time_frame>
    <description>Each section of prep score evaluating the right, mid, and left colon, as well as the fluid score will be analyzed individually</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Effects</measure>
    <time_frame>Up to 48 hours after procedure</time_frame>
    <description>Any adverse effects that may be attributed to the intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerability of the preparation</measure>
    <time_frame>Within 1 day of intervention</time_frame>
    <description>A questionnaire to assess the overall tolerability of the preparation.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">126</enrollment>
  <condition>Endoscopy</condition>
  <condition>Bowel Preparation Solutions</condition>
  <arm_group>
    <arm_group_label>PEG Lyte</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>PEGlyte to be reconstituted with 4L of water and taken in the evening before the colonoscopy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pico Salax Split</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two sachets of Pico-Salax with 1 taken the night before colonoscopy and the second taken the morning of colonoscopy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pico Salax Night Before</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 sachets of Pico Salax mixed with water taken about 4 hours apart the night before colonoscopy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bisacodyl 10mg</intervention_name>
    <description>Given at the start of the bowel preparation the day before colonoscopy</description>
    <arm_group_label>PEG Lyte</arm_group_label>
    <arm_group_label>Pico Salax Split</arm_group_label>
    <arm_group_label>Pico Salax Night Before</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Polyethelene Glycol</intervention_name>
    <description>280g reconstituted in 4 liters of water</description>
    <arm_group_label>PEG Lyte</arm_group_label>
    <other_name>PEG-Lyte</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Picosulfate sodium</intervention_name>
    <description>Two sachets, Each sachet has 10mg dose</description>
    <arm_group_label>Pico Salax Split</arm_group_label>
    <arm_group_label>Pico Salax Night Before</arm_group_label>
    <other_name>Pico-Salax</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Inpatient colonoscopy

          -  Age greater than 18 years old

          -  Able to give consent

        Exclusion Criteria:

          -  No consent obtained

          -  Pregnancy or lactating

          -  Renal impairment

          -  Severe CHF (NYHA class 3/4)

          -  Recent myocardial infarction (preceding 6 months)

          -  Ileus

          -  Ascites

          -  Severe Colitis

          -  Toxic Megacolon

          -  Gastrointestinal Obstruction

          -  PEG tube

          -  Previous large bowel resection

          -  Allergy to study drug
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Khurram J Khan, MD, BSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>St Josephs</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lisa Balogh Melanson, BSc</last_name>
    <phone>905-522-1155</phone>
    <phone_ext>33673</phone_ext>
    <email>lbalogh@stjosham.on.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>St Joseph Hospital</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N4A6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Balogh-Melanson, BSc</last_name>
      <phone>905-522-1155</phone>
      <phone_ext>33673</phone_ext>
      <email>lbalogh@stjosham.on.ca</email>
    </contact>
    <investigator>
      <last_name>Khurram J Khan, MD,BSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>David Morgan, MD, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Robert Spaziani, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Subhas Ganguli, MD, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Keith Tsoi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Subash Jalali, MBBS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Houssein Fergani, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Abbas Merali, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nauzer Forbes, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 19, 2012</study_first_submitted>
  <study_first_submitted_qc>June 22, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 25, 2012</study_first_posted>
  <last_update_submitted>January 28, 2013</last_update_submitted>
  <last_update_submitted_qc>January 28, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 30, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>St. Joseph's Healthcare Hamilton</investigator_affiliation>
    <investigator_full_name>Khurram Khan</investigator_full_name>
    <investigator_title>Assistant Professor of Medicine</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bisacodyl</mesh_term>
    <mesh_term>Picosulfate sodium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

